ClinicalTrials.gg
Not yet recruitingNCT07861828Immuno-DRYveUpdated Oct 6, 2026

Exploratory Study of the Efficacy of HuMoSCs (Human Monocyte-derived Suppressor Cells) on Glandular Involvement in Sjögren's Syndrome

An interventional study of Blood sample and Salivary gland biopsy in Sjogren's Syndrome and Autoimmune Diseases, sponsored by Centre Hospitalier Universitaire Dijon. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Centre Hospitalier Universitaire Dijon · Not applicable, Interventional, and Other

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 58 studies in Sjogren's Syndrome with a site in France — 18 open to participants now, 25 under way, 7 of them phase 3. Sjogren's Syndrome · France.

Planned enrollment
37th of 40
20 · median 169
Started
2026
with 6 others
No phase
12 of 58
5 open now
Primary completion
2028-10
later than 16 of 24 live
Registered
56th of 58
by date

Among the 58 studies in Sjogren's Syndrome with a site in France, this one is the 37th largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2026, is one of 12 with no phase, reaches primary completion later than 16 of the 24 other live ones, and was the 56th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

18 of the 58 studies in Sjogren's Syndrome with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sjogren's Syndrome with a site in France, or all of them as a file.
02

Study summary

Sjögren's syndrome is an autoimmune disease.

Dry syndrome is a key feature of this condition, almost always leading to dryness of the mouth and eyes. It manifests as a decrease in the production of saliva and tears, causing discomfort for patients. This chronic dryness contributes to oral and ocular conditions.

It is caused by lymphocytic infiltration of the exocrine glands, leading to their inflammation and subsequent fibrosis, which results in a decrease in fluid production by these glands.

This chronic inflammation causes fatigue in the patient. Furthermore, in 30 to 60% of cases, Sjögren's syndrome may involve extra-glandular involvement, most commonly affecting the joints, but also involving the lungs, nervous system, and kidneys. Additionally, patients with thisdisease have a higher risk of developing lymphoma compared to unaffected individuals.

The current treatment for Sjögren's syndrome is the same as that for dry eye syndrome; it is primarily symptomatic, involving lifestyle and dietary changes, the use of eye drops or oral lubricants, and medication to stimulate saliva production. To date, there is no medication available to treat Sjögren's syndrome and thus the cause of dry eye syndrome.

In our laboratory (INSERM 1098, UMR Right), we have developed cells that suppress the immune system (immunosuppressive cells) derived from human monocytes cultured ex vivo using a patented process called HuMoSC (Human Monocyte -derived Suppressor Cells). These cells possess strong immunosuppressive capacity, already demonstrated in vitro and in vivo in mouse models.

The aim of this study is to evaluate whether HuMoSCs can reduce the accumulation of immune cells and thereby decrease chronic inflammation and, in the longer term, limit the development of fibrosis (hardening with tissue destruction and scarring) in the salivary glands.

Biopsy of the accessory salivary glands is already part of the diagnostic process for Sjögren's syndrome. During this biopsy, additional accessory salivary glands will be collected and sent to the laboratory for this study. These glands will be cultured in the presence of HuMoSC supernatant, and the impact of this treatment will be analyzed.

03

Conditions studied

  • Sjogren's Syndrome
  • Autoimmune Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A person who has given verbal consent
  • A person exhibiting symptoms consistent with Sjögren's syndrome who is scheduled to undergo diagnostic testing

Exclusion criteria

Exclusion Criteria:

  • A person who is not enrolled in or eligible for a social security program
  • A person subject to a legal guardianship order (curatorship, guardianship)
  • A person subject to a court-ordered protective measure
  • Pregnant women, women in labor, or breastfeeding women
  • An adult who is legally incapacitated or unable to give consent
  • A minor
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Patients with Sjögren's syndrome

    Biological: Blood sample · Other: Salivary gland biopsy

Interventions

  • BiologicalBlood sample

    Collect 4 green tubes for cells and 2 tubes for serum

  • OtherSalivary gland biopsy

    Sampling of two accessory salivary glands

06

What researchers measure

Primary outcomes

  1. Percentage of the various subclasses of lymphocytes and macrophages

    To identify, using immunohistochemistry and cytokine analysis, a reduction in inflammatory infiltration (lymphocytes and macrophages) of the accessory salivary glands in the presence of HuMoSC supernatant.

    Time frame: 24 months

  2. Concentrations of inflammatory and anti-inflammatory cytokines in the culture supernatants of accessory salivary glands cultured with or without HuMoSC supernatant.

    Time frame: 24 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 39 non-industry interventional studies with no phase under Sjogren's Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 24 months is above that.

Counting every sponsor, half of 44 studies reached it within 18 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartEst.
Oct 10, 2026
Primary completionEst.
Oct 11, 2028
CompletionEst.
Oct 11, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07861828
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 10, 2026 (estimated)
Primary completion
Oct 11, 2028 (estimated)
Completion
Oct 11, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Bernard BONNOTTE
Contact
bernard.bonnotte@chu-dijon.fr
03 80 29 34 32 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion